Get started
Author

Alexander P. Yllanes

Observed names: Alex Y. Yllanes, Alex Yllanes, Alexander Yllanes
OpenAlex ID: A5037332413
Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
2018 · Gray R. Anderson, Suzanne E. Wardell, et al. · Nature Communications · 135
PDF
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer
2019 · Kimberly J. Cocce, Jeff S. Jasper, et al. · Cell Reports · 76
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
2017 · John D. Norris, Stephanie J. Ellison, et al. · Journal of Clinical Investigation · 56
PDF
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
2016 · Gray R. Anderson, Suzanne E. Wardell, et al. · Science Translational Medicine · 53
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
2019 · Suzanne E. Wardell, Alexander P. Yllanes, et al. · Breast Cancer Research and Treatment · 52
PDF
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2017 · James P. Stice, Suzanne E. Wardell, et al. · Molecular Cancer Research · 40
Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer
2017 · Suzanne E. Wardell, Alexander P. Yllanes, et al. · Cancer Research · 15
Morphine responsiveness to thermal pain stimuli is aging-associated and mediated by dopamine D1 and D3 receptor interactions
2017 · Sophia Samir, Alexander P. Yllanes, et al. · Neuroscience · 12
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
2019 · Suzanne E. Wardell, Alexander P. Yllanes, et al. · Breast Cancer Research and Treatment · 2
PDF
Abstract 1588: Effects of the selective CYP17-lyase and androgen receptor (AR) inhibitor, seviteronel, and the cyclin-dependent kinase (CDK) 4/6 inhibitor, G1T38, on tumor growth in an AR-V7+ castration-resistant prostate cancer (CRPC) xenograft model
2017 · Suzanne E. Wardell, Alexander P. Yllanes, et al. · Cancer Research · 1
Supplementary Figure Legends from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Supplementary Figures 1-4 from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Supplementary Figures 1-4 from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
PDF
Data from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Supplementary Figure Legends from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Data from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Abstract 2820: Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer
2016 · James P. Stice, Hannah S. White, et al. · Cancer Research
Works count: 17
Citation count: 442
H-index: 8
I10-index: 8
Year
Topic
Type